Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications
Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications · 15.12.2026 · III (04)
DOI: 10.62830/mmj3-04-4b ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications, online erschienen am 15.12.2026. Verfasst von Sinthia Mondal.
Abstract (Originalsprache)
Human leucocyte antigen (HLA) polymorphism is a major determinant of alloimmune recognition following transplantation, influencing graft-versus-host disease (GVHD) in allogeneic haematopoietic stem-cell transplantation (HSCT) and antibody-mediated rejection (AMR) in solid-organ transplantation. Although both involve alloimmune responses, their underlying mechanisms, tissue targets, diagnostic approaches, and therapeutic strategies differ substantially. Advances in HLA assessment, including high-resolution allele typing, HLA-DP and HLA-DQ evaluation, epitope and eplet analysis, and donor-specific antibody (DSA) profiling, have expanded the understanding of immunological risk. Emerging technologies, such as donor-derived cell-free deoxyribonucleic acid (DNA), transcriptomic assays, digital pathology, immune repertoire sequencing, and pharmacogenomics, offer additional opportunities for personalised transplant monitoring, although their clinical utility requires further validation. Therapeutic advances have similarly expanded treatment options. Targeted agents, including ruxolitinib for steroid-refractory acute GVHD, and belumosudil and axatilimab for chronic GVHD, represent important developments in pathway-directed therapy. In AMR, antibody removal, B-cell depletion, plasma-cell targeting, complement inhibition, and costimulatory blockade address different components of humoral alloimmunity, although effective long-term management of chronic AMR remains challenging. The convergence of advanced HLA typing, molecular diagnostics, biomarker-guided monitoring, and targeted therapeutics offers significant opportunities for precision transplantation. Integrating these approaches into clinical practice and pharmaceutical development will require reproducible assays, robust clinical validation, and evidence that their implementation improves meaningful patient outcomes.
Zitieren
APA
Mondal, S. (2026). Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications. Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications, III(04). https://doi.org/10.62830/mmj3-04-4b
Vancouver
Mondal S. Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications. Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications. 2026;III(04). doi:10.62830/mmj3-04-4b
BibTeX
@article{Mondal2026,
author = {Mondal, Sinthia},
title = {Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications},
journal = {Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications},
year = {2026},
volume = {III},
number = {04},
doi = {10.62830/mmj3-04-4b}
}
EUVIMED